BACKGROUND: The no-reflow phenomenon is characterized by an inadequate myocardial tissue perfusion in the presence of a patent epicardial coronary artery. The incidence of no-reflow appears to be highest in patients undergoing primary percutaneous coronary intervention (PCI) in acute myocardial infarction or during PCI of saphenous vein grafts (SVGs). Treatment of no-reflow phenomenon is based on the intracoronary administration of medications that induce vasodilatation in small distal coronary vasculature. Sodium nitroprusside (NTP) is a direct nitric oxide donor and does not require intracellular metabolism to induce vasodilatation in microcirculation. CASE STUDY: Two patients are reported, in whom no-reflow following primary PCI of SVG and native coronary artery was successfully treated with intracoronary NTP. Repeated injections of 50 microg NTP were given selectively distal to the occlusion site utilizing coronary microcatheter (a total NTP dose of 200 microg was given in both cases). Because of the extremely short half-life, the use of intracoronary NTP was easily tolerated by both patients, without causing prolonged or profound hypotension. CONCLUSION: The authors therefore propose the use of NTP for treatment of no-reflow phenomenon in both vein grafts and native coronary arteries in the setting of acute myocardial infarction.
BACKGROUND: The no-reflow phenomenon is characterized by an inadequate myocardial tissue perfusion in the presence of a patent epicardial coronary artery. The incidence of no-reflow appears to be highest in patients undergoing primary percutaneous coronary intervention (PCI) in acute myocardial infarction or during PCI of saphenous vein grafts (SVGs). Treatment of no-reflow phenomenon is based on the intracoronary administration of medications that induce vasodilatation in small distal coronary vasculature. Sodium nitroprusside (NTP) is a direct nitric oxidedonor and does not require intracellular metabolism to induce vasodilatation in microcirculation. CASE STUDY: Two patients are reported, in whom no-reflow following primary PCI of SVG and native coronary artery was successfully treated with intracoronary NTP. Repeated injections of 50 microg NTP were given selectively distal to the occlusion site utilizing coronary microcatheter (a total NTP dose of 200 microg was given in both cases). Because of the extremely short half-life, the use of intracoronary NTP was easily tolerated by both patients, without causing prolonged or profound hypotension. CONCLUSION: The authors therefore propose the use of NTP for treatment of no-reflow phenomenon in both vein grafts and native coronary arteries in the setting of acute myocardial infarction.
Authors: S Jiménez Valero; R Moreno; R Martin Reyes; A Sánchez Recalde; G Galeote; L Calvo; A Villate; J L López Sendón Journal: Cardiovasc Hematol Agents Med Chem Date: 2008-04
Authors: Guy Amit; Carlos Cafri; Sergei Yaroslavtsev; Shmuel Fuchs; Ora Paltiel; Akram Abu-Ful; Jean M Weinstein; Arik Wolak; Reuben Ilia; Doron Zahger Journal: Am Heart J Date: 2006-11 Impact factor: 4.749
Authors: Costantino O Costantini; Gregg W Stone; Roxana Mehran; Eve Aymong; Cindy L Grines; David A Cox; Thomas Stuckey; Mark Turco; Bernard J Gersh; James E Tcheng; Eulogio Garcia; John J Griffin; Giulio Guagliumi; Martin B Leon; Alexandra J Lansky Journal: J Am Coll Cardiol Date: 2004-07-21 Impact factor: 24.094
Authors: Keyur H Parikh; Milan C Chag; Kanan J Shah; Urmil G Shah; Hemang A Baxi; Anish H Chandarana; Ajay M Naik; Joyal N Shah; Hetal D Shah; Ramesh K Goyal Journal: Can J Physiol Pharmacol Date: 2007 Mar-Apr Impact factor: 2.273
Authors: Jason Schultz; Nicolas Segal; James Kolbeck; Emily Caldwell; Marit Thorsgard; Scott McKnite; Tom P Aufderheide; Keith G Lurie; Demetris Yannopoulos Journal: Resuscitation Date: 2011-12 Impact factor: 5.262
Authors: Demetris Yannopoulos; Timothy Matsuura; Jason Schultz; Kyle Rudser; Henry R Halperin; Keith G Lurie Journal: Crit Care Med Date: 2011-06 Impact factor: 7.598